Other formats:
BibTeX
LaTeX
RIS
@article{1215472, author = {Hidalgo, Manuel and Amant, Frederic and Biankin, Andrew V. and Budinská, Eva and Byrne, Annete T. and Caldas, Carlos and Clarke, Robert B. and Jong, Steven de and Jonkers, Jos and Maelandsmo, Gundhild Mari and RomanandRoman, Sergio and Seoane, Joan and Trusolino, Livio and Villanueva, Alberto}, article_location = {Philadelphia}, article_number = {9}, doi = {http://dx.doi.org/10.1158/2159-8290.CD-14-0001}, keywords = {HUMAN PANCREATIC-CANCER; TUMOR XENOGRAFTS; NUDE-MICE; COLORECTAL-CANCER; STEM-CELLS; IN-VIVO; PERSONALIZED CHEMOTHERAPY; THERAPEUTIC RESPONSE; IMMUNODEFICIENT MICE; DRUG DEVELOPMENT}, language = {eng}, issn = {2159-8274}, journal = {Cancer Discovery}, title = {Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research}, volume = {4}, year = {2014} }
TY - JOUR ID - 1215472 AU - Hidalgo, Manuel - Amant, Frederic - Biankin, Andrew V. - Budinská, Eva - Byrne, Annete T. - Caldas, Carlos - Clarke, Robert B. - Jong, Steven de - Jonkers, Jos - Maelandsmo, Gundhild Mari - Roman-Roman, Sergio - Seoane, Joan - Trusolino, Livio - Villanueva, Alberto PY - 2014 TI - Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research JF - Cancer Discovery VL - 4 IS - 9 SP - 998-1013 EP - 998-1013 PB - American Association for Cancer Research Inc. SN - 21598274 KW - HUMAN PANCREATIC-CANCER KW - TUMOR XENOGRAFTS KW - NUDE-MICE KW - COLORECTAL-CANCER KW - STEM-CELLS KW - IN-VIVO KW - PERSONALIZED CHEMOTHERAPY KW - THERAPEUTIC RESPONSE KW - IMMUNODEFICIENT MICE KW - DRUG DEVELOPMENT N2 - Recently, there has been an increasing interest in the development and characterization of patient-derived tumor xenograft (PDX) models for cancer research. PDX models mostly retain the principal histologic and genetic characteristics of their donor tumor and remain stable across passages. These models have been shown to be predictive of clinical outcomes and are being used for preclinical drug evaluation, biomarker identification, biologic studies, and personalized medicine strategies. This article summarizes the current state of the art in this field, including methodologic issues, available collections, practical applications, challenges and shortcomings, and future directions, and introduces a European consortium of PDX models. Significance: PDX models are increasingly used in translational cancer research. These models are useful for drug screening, biomarker development, and the preclinical evaluation of personalized medicine strategies. This review provides a timely overview of the key characteristics of PDX models and a detailed discussion of future directions in the field. ER -
HIDALGO, Manuel, Frederic AMANT, Andrew V. BIANKIN, Eva BUDINSKÁ, Annete T. BYRNE, Carlos CALDAS, Robert B. CLARKE, Steven de JONG, Jos JONKERS, Gundhild Mari MAELANDSMO, Sergio ROMAN-ROMAN, Joan SEOANE, Livio TRUSOLINO and Alberto VILLANUEVA. Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research. \textit{Cancer Discovery}. Philadelphia: American Association for Cancer Research Inc., 2014, vol.~4, No~9, p.~998-1013. ISSN~2159-8274. Available from: https://dx.doi.org/10.1158/2159-8290.CD-14-0001.
|